Skip to content
Reviewed against editorial standards · Updated 2026-05-13

Ipamorelin: Dosage & Administration

Part of the Ipamorelin Complete Guide

Partner

Ipamorelin (10mg)

BioLongevity Labs15% Off
Shop Ipamorelin

Advertiser link — we may earn a commission at no extra cost to you.

Ipamorelin Dosage Protocols

Ipamorelin is the first identified selective growth hormone secretagogue, originally characterized by Novo Nordisk researchers in 1998.[1] Its defining feature is selectivity — it stimulates GH release through the GHSR-1a receptor without significantly affecting cortisol, prolactin, ACTH, or appetite (unlike GHRP-2 and GHRP-6).

ProtocolDoseFrequencyTimingApplication
Standalone (low-end)100–200 mcg1× dailyBedtime, fastedConservative starting protocol
Standalone (standard)200–300 mcg2–3× dailyFasted — bedtime primaryMost-published research dose
Standalone (higher)300–500 mcg2–3× dailyFasted — bedtime primaryOlder / more GH-deficient adults
With CJC-1295 (Mod GRF 1-29)200 mcg + 100 mcg CJC2–3× dailyFasted — bedtime primaryMost common research stack
Higher CJC stack300 mcg + 200 mcg CJC2–3× dailyFasted — bedtime primaryMore robust GH amplification

The CJC-1295 (no DAC, also called Mod GRF 1-29) plus ipamorelin combination is the most common GH peptide stack in research. The GHRH analog (CJC-1295) and ghrelin-receptor agonist (ipamorelin) activate two complementary signaling pathways, producing synergistic GH release 2–3× greater than either alone.[2]

Body Weight Considerations

Ipamorelin's published dosing is not strictly body-weight scaled, but practical adjustments help:

  • Under 70 kg (155 lbs): 100–200 mcg per dose typically sufficient
  • 70–100 kg (155–220 lbs): 200–300 mcg per dose — standard research range
  • Over 100 kg (220 lbs): 300–400 mcg per dose, or 200 mcg three times daily

Unlike hexarelin, ipamorelin does not produce predictable receptor desensitization with chronic use — the same dose remains effective over standard 8–12 week cycles. Going above 500 mcg per dose does not produce meaningful additional GH release; the pituitary's maximum response is achieved at moderate doses.[3]

Reconstitution Math

Ipamorelin typically comes as lyophilized powder in 2 mg, 5 mg, or 10 mg vials. Common reconstitutions:

VialBAC waterConcentration200 mcg dose300 mcg dose
2 mg1 mL2 mg/mL (2,000 mcg/mL)0.1 mL (10 units)0.15 mL (15 units)
2 mg2 mL1 mg/mL0.2 mL (20 units)0.3 mL (30 units)
5 mg2.5 mL2 mg/mL0.1 mL (10 units)0.15 mL (15 units)
5 mg5 mL1 mg/mL0.2 mL (20 units)0.3 mL (30 units)
10 mg5 mL2 mg/mL0.1 mL (10 units)0.15 mL (15 units)

Use the peptide calculator for precise volumes for your specific vial. See the reconstitution guide for technique.

Why Fasted Timing Matters

Like all GH secretagogues, ipamorelin's GH-releasing effect is dramatically suppressed by food. The mechanism is well-characterized:

  • Carbohydrates and fats raise insulin, which suppresses GH release at the pituitary.
  • Elevated postprandial somatostatin further inhibits GH.
  • Protein dampens GH less than carbohydrates but still reduces the effect.

Standard rule: no food for at least 2 hours before injection, 30 minutes after.

Optimal dose timing

  • Bedtime (most important): at least 2 hours after dinner. Amplifies the largest natural GH pulse during slow-wave sleep.
  • Morning fasted: first thing on waking, before breakfast. Reasonable secondary dose.
  • Pre-workout fasted: at least 2 hours after the last meal. Pairs with exercise-induced GH pulse.
  • Post-workout: if used, fast for at least 30 minutes after dose before refueling.

Cycle Length & Long-Term Use

Ipamorelin's lack of receptor desensitization (unlike hexarelin) means longer cycles are practical:

  • Standard cycle: 8–12 weeks on / 4–8 weeks off.
  • Extended use: some research protocols run 16+ weeks continuously without diminished response, but most users prefer cycling for monitoring purposes.
  • IGF-1 monitoring: for protocols running > 12 weeks, baseline and periodic IGF-1 levels help track response. Sustained IGF-1 elevation > 350 ng/mL warrants dose reduction or break.

The CJC-1295 / ipamorelin stack does not produce desensitization either — but the CJC-1295 DAC version does (different molecule). If using a "stack" that contains DAC, expect the GH response to diminish over time.

Storage

  • Lyophilized vials: -20°C long-term, or 2–8°C (refrigerator) for shorter-term storage.
  • Reconstituted: refrigerate at 2–8°C. Use within 28 days.
  • Protect from light in the original packaging or opaque container.
  • Avoid freeze-thaw of the reconstituted solution.

See the peptide storage guide for complete guidelines.

FAQ

Frequently Asked Questions

References

  1. [1] Raun K, Hansen BS, Johansen NL, et al.. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998.
  2. [2] Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sexual Medicine Reviews, 2018.
  3. [3] Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 1999.
  4. [4] Beck DE, Sweeney WB, McCarter MD, et al.. Prospective, randomized, controlled trial of edrecolomab/ipamorelin in postoperative ileus. International Journal of Colorectal Disease, 2014.

Researching peptides? We did the hard part.

Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.

No spam · Unsubscribe anytime

Related Reading

AD
Austin Danner

Founder & Editor in Chief

Founder of Peptides Insider. Independent researcher focused on translating peer-reviewed peptide research into practical, evidence-based guides.

Reviewed against Peptides Insider editorial standards · Last reviewed 2026-05-13.